Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-18
2006-04-18
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S455000, C424S486000
Reexamination Certificate
active
07030155
ABSTRACT:
A method of making an emulsion of tocopherol incorporating a co-solvent and, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans by various routes, is disclosed. Also included in the emulsion is PEGylated vitamin E. PEGylated α-tocopherol includes polyethylene glycol subunits attached by a succinic acid diester at the ring hydroxyl of vitamin E and serves as a primary surfactant, stabilizer and a secondary solvent in emulsions of α-tocopherol.
REFERENCES:
patent: 4439432 (1984-03-01), Peat
patent: 4551332 (1985-11-01), Stillman
patent: 4578391 (1986-03-01), Kawata et al.
patent: 4784845 (1988-11-01), Desai et al.
patent: 4797285 (1989-01-01), Barenholz et al.
patent: 4898735 (1990-02-01), Barenholz et al.
patent: 4960814 (1990-10-01), Wu et al.
patent: 5002767 (1991-03-01), Masse
patent: 5041278 (1991-08-01), Janoff et al.
patent: 5114957 (1992-05-01), Hendler et al.
patent: 5179122 (1993-01-01), Greene et al.
patent: 5330689 (1994-07-01), Janoff et al.
patent: 5387579 (1995-02-01), Maybeck et al.
patent: 5391377 (1995-02-01), Barnwell
patent: 5407683 (1995-04-01), Shively
patent: 5478860 (1995-12-01), Wheeler et al.
patent: 5504102 (1996-04-01), Agharkar et al.
patent: 5532002 (1996-07-01), Story
patent: 5534499 (1996-07-01), Ansell
patent: 5573781 (1996-11-01), Brown et al.
patent: 5583105 (1996-12-01), Kovacs et al.
patent: 5614549 (1997-03-01), Greenwald et al.
patent: 5616330 (1997-04-01), Kaufman et al.
patent: 5621001 (1997-04-01), Canetta et al.
patent: 5626869 (1997-05-01), Nyqvist et al.
patent: 5648506 (1997-07-01), Desai et al.
patent: 5653998 (1997-08-01), Hamann et al.
patent: 5681846 (1997-10-01), Trissel
patent: 5683715 (1997-11-01), Boni et al.
patent: 5726181 (1998-03-01), Hausheer et al.
patent: 5877205 (1999-03-01), Andersson
patent: 6458373 (2002-10-01), Lambert et al.
patent: 6667048 (2003-12-01), Quay et al.
patent: 2003/0104015 (2003-06-01), Lambert et al.
patent: 2003/0147959 (2003-08-01), Lambert et al.
patent: 2004/0202712 (2004-10-01), Lambert et al.
patent: B-24213/88 (1992-02-01), None
patent: B-70937/91 (1994-09-01), None
patent: B-27266/92 (1995-04-01), None
patent: 0 001 851 (1979-05-01), None
patent: 0 299 528 (1988-07-01), None
patent: 0 546 951 (1992-12-01), None
patent: 0382 779 (1993-08-01), None
patent: 0 700 679 (1995-08-01), None
patent: 0 712 631 (1996-05-01), None
patent: 0 474 647 (1997-02-01), None
patent: WO 88/06442 (1988-09-01), None
patent: WO 89/03689 (1989-05-01), None
patent: WO 92/13531 (1992-08-01), None
patent: WO 94/12154 (1994-06-01), None
patent: WO 94/20143 (1994-09-01), None
patent: WO 95/01785 (1995-01-01), None
patent: WO 95/11039 (1995-04-01), None
patent: WO 95/20943 (1995-08-01), None
patent: WO 95/24892 (1995-09-01), None
patent: WO 95/25504 (1995-09-01), None
patent: WO 95/31217 (1995-11-01), None
patent: WO 96/15774 (1996-05-01), None
patent: WO 96/17593 (1996-06-01), None
patent: WO 96/17594 (1996-06-01), None
patent: WO 96/17899 (1996-06-01), None
patent: WO 96/22103 (1996-07-01), None
patent: WO 96/32094 (1996-10-01), None
patent: WO 96/33697 (1996-10-01), None
patent: WO 96/33987 (1996-10-01), None
patent: WO 96/40056 (1996-12-01), None
patent: WO 97/03651 (1997-02-01), None
patent: WO 97/07113 (1997-02-01), None
patent: WO 97/09964 (1997-03-01), None
patent: WO 97/10849 (1997-03-01), None
patent: WO 97/11682 (1997-04-01), None
patent: WO 97/13528 (1997-04-01), None
patent: WO 97/14705 (1997-04-01), None
patent: WO 97/22358 (1997-06-01), None
patent: WO 97/23192 (1997-07-01), None
patent: WO 97/28151 (1997-08-01), None
patent: WO 97/30695 (1997-08-01), None
patent: WO 97/29773 (1997-09-01), None
patent: WO 97/33552 (1997-09-01), None
patent: WO 97/36611 (1997-10-01), None
patent: WO 97/44124 (1997-11-01), None
patent: WO 97/46204 (1997-12-01), None
patent: WO 98/00110 (1998-01-01), None
patent: WO 98/00128 (1998-01-01), None
patent: WO 98/08597 (1998-03-01), None
patent: WO 98/11902 (1998-03-01), None
patent: WO 98/18321 (1998-05-01), None
patent: WO 98/21197 (1998-05-01), None
patent: WO 98/30204 (1998-07-01), None
patent: WO 98/30205 (1998-07-01), None
patent: WO 98/37869 (1998-09-01), None
patent: WO 98/40051 (1998-09-01), None
patent: WO 98/40094 (1998-09-01), None
patent: WO 99/04787 (1999-02-01), None
patent: WO 00/50007 (2000-08-01), None
Alade, S., et al., “Polysorbate 80 and E-Ferol Toxicity,”Pediatrics7(4):593-597, 1986.
Alkan-Onyuksel, H., “A Mixed Micellar Formulation Suitable for the Parenteral Administration of Taxol,”Pharm. Res. 2(2):206-212, 1994.
Arrowsmith, J., et al., “Morbidity and Mortality Among Low Birth Weight Infants Exposed to an Intravenous Vitamin E Product, E-Ferol,”Pediatrics873(2), 1989.
Balistreri, W., et al., “Lessons From the E-Ferol Tragedy,”Pediatrics78(3), 1986.
Bateman, N.E., et al., “Kinetics of D-α- Tocopherol in a Water Soluble Base in Man,”J. Pharm. Pharmacol. 37:728-729, 1985.
Bignami, G., et al., “Biological Activity of 26-Succinylbryostatin 1,”Biochim. Biophys. Acta1312:197-206, 1996.
Brunzell, J.D., et al., “Pathophysiology of Lipoprotein Transport,”Metabolism27(9):1109-1127, 1976.
Cherng-Chyi Fu, R. et al., “The Biocompatibility of Parenteral Vehicles—In Vitro/In Vivo Screening Comparison and the Effect of Excipients on Hemolysis,”J. Parenter. Sci. Technol. 41(5):164-168, 1987.
Constantinides, P.P., “Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects,”Pharm. Res. 12(11):1561-1572, 1995.
Coon, J.S., et al., “Solutol HS 15, Nontoxic Polyoxyethylene Esters of 12-Hydroxystearic Acid, Reverses Multidrug Resistance,”Cancer Res. 51:897-902, 1991.
Dasgupta, J., et al., “Vitamin E. Its Status and Role in Leukemia and Lymphoma,”Neoplasma40(4):235-240, 1993.
Davis, S.S., et al., “Lipid Emulsions as Drug Delivery Systems,”Ann. N. Y. Acad. Sci. 507:75-88, 1987.
“EastmanVitamin E TPGS: Products and Applications,”Publication EFC-226, Eastman Chemical Company, Oct. 1996.
Farah, N., et al., “Self-Microemulsifying Drug Delivery Systems for Improving In-Vitro Dissolution of Drugs,”AAPS Annual Meeting, Orlando, Florida, 1993, 5 pages.
Fariss, M., et al., “The Selective Antiproliferative Effects of α-Tocopheryl Hemisuccinate and Cholesteryl Hemisuccinate on Murine Leukemia Cells Result From the Action of the Intact Compounds,”Cancer Res. 54:3346-3351, 1994.
Geetha, A., “α-Tocopherol Reduces Doxorubicin-Induced Toxicity in Rats—Histological and Biochemical Evidences.”Ind. J. Physiol. Pharmac. 34(2):94-100, 1990.
Hadfield, J.I.H., “Preoperative Intravenous Fat Therapy,”Brit. J. Surg. 52(4):291-298, 1965.
Hansrani, P.K., et al., “The Preparation and Properties of Sterile Intravenous Emulsions,”J. Parenter. Sci. Technol. 37:145-150, 1983.
Heird, W.C., et al., “Total Parenteral Nutrition: Medical Progress,”J. Pediatr. 86(2):2-16, 1975.
Hidiroglou, M., et al., “Pharmacokinetic Disposition in Sheep of Various Vitamin E Preparations Given Orally or Intravenously,”Brit. J. Nutr. 59:509-518, 1988.
Ingold, K.U., et al., “Autoxidation of Lipids and Antioxidation by α-Tocopherol and Ubiquinol in Homogeneous Solution and in Aqueous Dispersions of Lipids: Unrecognized Consequences of Lipid Particle Size as Exemplified by Oxidation of Human Low Density Lipoprotein,”Proc. Natl. Acad. Sci. USA90:45-49, 1993.
Israel, K. et al., “RRR-α-Tocopheryl Succinate Inhibits the Proliferation of Human Prostatic Tumor Cells With Defective Cell Cyle/Differentiation Pathways.”Nutr. Cancer24(2):161-169, 1995.
Kagkadis, K.A., et al., “A Freeze-Dried Injectable Form of Ibuprofen: Development and Optimisation Using Response Surface Mehtodology,”PDA J. Pharm. Sci. T
Constantinides Panayiotis P.
Lambert Karel J.
Quay Steven C.
Tustian Alexander K.
Christensen O'Connor Johnson & Kindness PLLC
Delacroix-Muirheid C.
Low Christopher S. F.
Sonus Pharmaceuticals Inc.
LandOfFree
Emulsion vehicle for poorly soluble drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Emulsion vehicle for poorly soluble drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Emulsion vehicle for poorly soluble drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586624